Chronic Migraine: Risk Factors, Mechanisms and Treatment

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2016 Jul 9

PMID 27389092

Citations 228

Authors

Arne May

Laura H Schulte

Affiliations

Soon will be listed here.

Abstract

Chronic migraine has a great detrimental influence on a patient's life, with a severe impact on socioeconomic functioning and quality of life. Chronic migraine affects 1-2% of the general population, and about 8% of patients with migraine; it usually develops from episodic migraine at an annual conversion rate of about 3%. The chronification is reversible: about 26% of patients with chronic migraine go into remission within 2 years of chronification. The most important modifiable risk factors for chronic migraine include overuse of acute migraine medication, ineffective acute treatment, obesity, depression and stressful life events. Moreover, age, female sex and low educational status increase the risk of chronic migraine. The pathophysiology of migraine chronification can be understood as a threshold problem: certain predisposing factors, combined with frequent headache pain, lower the threshold of migraine attacks, thereby increasing the risk of chronic migraine. Treatment options include oral medications, nerve blockade with local anaesthetics or corticoids, and neuromodulation. Well-defined diagnostic criteria are crucial for the identification of chronic migraine. The International Headache Society classification of chronic migraine was recently updated, and now allows co-diagnosis of chronic migraine and medication overuse headache. This Review provides an up-to-date overview of the classification of chronic migraine, basic mechanisms and risk factors of migraine chronification, and the currently established treatment options.

Citing Articles

Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study).

Iannone L, Vaghi G, Sebastianelli G, Casillo F, Russo A, Silvestro M J Headache Pain. 2025; 26(1):4.

PMID: 39762740 PMC: 11702052. DOI: 10.1186/s10194-024-01935-8.

Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.

Tanei T, Fuse Y, Maesawa S, Nishimura Y, Ishizaki T, Nagashima Y Heliyon. 2025; 10(22):e40190.

PMID: 39748981 PMC: 11693917. DOI: 10.1016/j.heliyon.2024.e40190.

Extra-axial inflammatory signal and its relationship to peripheral and central immunity in depression.

Eiff B, Bullmore E, Clatworthy M, Fryer T, Pariante C, Mondelli V Brain. 2024; 148(2):635-646.

PMID: 39657983 PMC: 11788198. DOI: 10.1093/brain/awae343.

Metformin attenuates central sensitization by regulating neuroinflammation through the TREM2-SYK signaling pathway in a mouse model of chronic migraine.

Fan Z, Su D, Li Z, Sun S, Ge Z J Neuroinflammation. 2024; 21(1):318.

PMID: 39627853 PMC: 11613737. DOI: 10.1186/s12974-024-03313-2.

The Impact of COVID-19 on Migraine: The Patients' Perspective.

Torrente A, Alonge P, Baschi R, Pilati L, Di Stefano V, Camarda C Life (Basel). 2024; 14(11).

PMID: 39598218 PMC: 11595852. DOI: 10.3390/life14111420.

References

Vieira D, Masruha M, Goncalves A, Zukerman E, Senne Soares C, Naffah-Mazzacoratti M . Idiopathic intracranial hypertension with and without papilloedema in a consecutive series of patients with chronic migraine. Cephalalgia. 2008; 28(6):609-13. DOI: 10.1111/j.1468-2982.2008.01564.x. View

Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L . Topiramate in the treatment of chronic migraine. Cephalalgia. 2003; 23(8):820-4. DOI: 10.1046/j.1468-2982.2003.00592.x. View

Maniyar F, Sprenger T, Monteith T, Schankin C, Goadsby P . Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2013; 137(Pt 1):232-41. DOI: 10.1093/brain/awt320. View

Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck R . Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995; 1(7):658-60. DOI: 10.1038/nm0795-658. View

Mauskop A . Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia. 2005; 25(2):82-6. DOI: 10.1111/j.1468-2982.2005.00611.x. View

Rossi P, Jensen R, Nappi G, Allena M . A narrative review on the management of medication overuse headache: the steep road from experience to evidence. J Headache Pain. 2009; 10(6):407-17. PMC: 3476213. DOI: 10.1007/s10194-009-0159-6. View

Bigal M, Lipton R . Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006; 67(2):252-7. DOI: 10.1212/01.wnl.0000225052.35019.f9. View

Zwart J, Dyb G, Hagen K, Svebak S, Holmen J . Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology. 2003; 61(2):160-4. DOI: 10.1212/01.wnl.0000069924.69078.8d. View

Aurora S, Dodick D, Turkel C, DeGryse R, Silberstein S, Lipton R . OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30(7):793-803. DOI: 10.1177/0333102410364676. View

10.

Bigal M, Serrano D, Reed M, Lipton R . Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008; 71(8):559-66. DOI: 10.1212/01.wnl.0000323925.29520.e7. View

11.

Freitag F, Collins S, CARLSON H, Goldstein J, Saper J, Silberstein S . A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002; 58(11):1652-9. DOI: 10.1212/wnl.58.11.1652. View

12.

Khalil M, Zafar H, Quarshie V, Ahmed F . Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K. J Headache Pain. 2014; 15:54. PMC: 4166400. DOI: 10.1186/1129-2377-15-54. View

13.

Saper J, Lake 3rd A, Cantrell D, Winner P, White J . Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002; 42(6):470-82. DOI: 10.1046/j.1526-4610.2002.02122.x. View

14.

Ashina S, Serrano D, Lipton R, Maizels M, Manack A, Turkel C . Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012; 13(8):615-24. PMC: 3484253. DOI: 10.1007/s10194-012-0479-9. View

15.

Nestoriuc Y, Martin A . Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2006; 128(1-2):111-27. DOI: 10.1016/j.pain.2006.09.007. View

16.

Diener H, Bussone G, van Oene J, Lahaye M, Schwalen S, Goadsby P . Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7):814-23. DOI: 10.1111/j.1468-2982.2007.01326.x. View

17.

Youssef A, Macefield V, Henderson L . Pain inhibits pain; human brainstem mechanisms. Neuroimage. 2015; 124(Pt A):54-62. DOI: 10.1016/j.neuroimage.2015.08.060. View

18.

De Simone R, Ranieri A . The role of intracranial hypertension in the chronification of migraine. Neurol Sci. 2015; 36 Suppl 1:23-8. DOI: 10.1007/s10072-015-2164-7. View

19.

Silberstein S, Lipton R, Dodick D, Freitag F, Ramadan N, Mathew N . Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007; 47(2):170-80. DOI: 10.1111/j.1526-4610.2006.00684.x. View

20.

Cosentino G, Fierro B, Vigneri S, Talamanca S, Paladino P, Baschi R . Cyclical changes of cortical excitability and metaplasticity in migraine: evidence from a repetitive transcranial magnetic stimulation study. Pain. 2014; 155(6):1070-1078. DOI: 10.1016/j.pain.2014.02.024. View